Life Sciences

Inomagen Therapeutics

Northwestern University

Inomagen Therapeutics is a biotechnology company pioneering a revolutionary gene therapy and first in class medical device in order to improve the treatment of atrial fibrillation (AF). Founded by Dr. Rishi Arora MD, our research has identified several major genes responsible for the oxidative damage and electrical remodeling that occurs in the heart following the onset of AF. If untreated, these changes often lead to the development of chronic AF, a condition that is often refractory to existing treatment modalities. Using a targeted gene therapy delivered by a proprietary cardiac catheter, Inomagen can silence expression of these detrimental genes and dramatically lower the risk of recurrent AF leading to better patient outcomes and significant cost savings.

This company will be presenting on Day 3 of DeepTechU 2022. View schedule >>